Form 4: SELLAS Life Sciences Executive Dragan Cicic Reports Stock Transaction

Dragan Cicic, SVP and Chief Development Officer at SELLAS Life Sciences, sold 8,256 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

Summary

• Dragan Cicic, a Senior Vice President and Chief Development Officer at SELLAS Life Sciences Group, Inc., reported a transaction involving the company's common stock.
• On December 4, 2024, Mr. Cicic disposed of 8,256 shares of common stock at a price of $1.13 per share.
• This transaction was to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• Following the transaction, Mr. Cicic directly owns 115,328 shares of SELLAS Life Sciences common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing of an insider stock transaction, which is neither positive nor negative for the company's overall outlook.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. It provides transparency into the stock dealings of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The transaction is typical for executives receiving stock-based compensation, where shares are often sold to cover tax liabilities upon vesting.
• Similar filings are made by executives at comparable biotech companies such as BioNTech, Moderna, and Regeneron when they sell shares.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale of shares by an executive to cover tax obligations.

Key Dates

Keywords

SELLAS Life Sciences, Dragan Cicic, stock transaction, Form 4, insider trading, restricted stock units, tax withholding